PubRank

V Diéras

Author PubWeight™ 25.42‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2011 1.82
2 Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol 2010 1.35
3 Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol 2008 1.33
4 Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol 2008 1.31
5 Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol 2012 1.22
6 Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy. Cancer 2001 1.17
7 Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response. Eur J Cancer 2003 1.14
8 Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 2010 1.12
9 Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000 1.12
10 First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013 1.12
11 Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001 1.07
12 HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer 2007 0.98
13 Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer. Eur J Cancer 2000 0.98
14 The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer 2003 0.98
15 Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents. Br J Cancer 2012 0.87
16 Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast 2004 0.87
17 Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90). Br J Cancer 1998 0.86
18 Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Ann Oncol 2013 0.85
19 Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2. Br J Cancer 2012 0.84
20 Expert perspectives on biosimilar monoclonal antibodies in breast cancer. Breast Cancer Res Treat 2014 0.83
21 Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study. Ann Oncol 1998 0.80
22 Is primary chemotherapy useful for all patients with primary invasive breast cancer? Recent Results Cancer Res 1998 0.78
23 Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. Semin Oncol 1997 0.78
24 A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. Br J Cancer 2008 0.77
25 Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients. Ann Oncol 2001 0.76
26 Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma. Gynecol Oncol 1997 0.75
27 [Epidemiology and economics of chemotherapy combinations in the treatment of advanced breast cancer]. Therapie 2000 0.75
28 First line protracted venous infusion fluorouracil with CisDDP or carboplatine in advanced colorectal cancer. Clin Ter 1997 0.75
29 First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer. J Infus Chemother 1996 0.75
30 Differential expression of Bax and Bcl-2 in the assessment of cellular dynamics in fine-needle samples of primary breast carcinomas. Cytometry 2000 0.75
31 Meningeal carcinomatosis in HER2-overexpressing breast cancers. J Neurooncol 2009 0.75